10 Results for "

HL7702

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "HL7702" in MCE Product Catalog:

Cat. No.: HY-151257
CAS No.: 2414484-25-4
Purity:  99.05%
Target:  

Hippo (MST)

Research Areas:  

Metabolic Disease

IHMT-MST1-58 is a potent, selective mammalian and orally active STE20-like protein 1 kinase (MST1) inhibitor with IC50 value of 23 nM. IHMT-MST1-58 can be used for the research of Type 1/2 diabetes .
loading...
    loading...
Cat. No.: HY-144826
CAS No.: 2668297-70-7
Target:  

GSK-3

Research Areas:  

Neurological Disease

ZDWX-25 is a highly potent GSK-3β and DYRK1A dual inhibitor with an IC50 value of 71 nM for GSK-3β. ZDWX-25 possesses significant cytotoxic activities against SH-SY5Y and HL-7702 cells. ZDWX-25 can be used for researching alzheimer's disease .
loading...
    loading...
Cat. No.: HY-155052
CAS No.: 2642327-52-2
Research Areas:  

Cancer

PAD4-IN-2 is a highly tumor-targeted and irreversible PAD4 inhibitor with an IC50 of 1.94 μM. It selectively recognizes sialic acid on tumor surfaces and accumulates in tumor tissues, with distribution in the cytoplasm of tumor cells and nuclei of neutrophils. PAD4-IN-2 inhibits the PAD4-H3cit-NETs (Neutrophil Extracellular Traps) pathway, reduces senescent tumor-associated neutrophils, and promotes M1 macrophage polarization. The compound exhibits potent anti-tumor and anti-metastatic activities and is suitable for breast cancer research .
loading...
    loading...
Cat. No.: HY-N12711
CAS No.: 224957-12-4
Calycosin 7-O-xylosylglucoside exhibits hepatoprotective efficacy in human hepatic cell HL-7702 through scavenging oxidative damage and antioxidant properties .
loading...
    loading...
Cat. No.: HY-155052A
Purity:  95.64%
Research Areas:  

Cancer

PAD4-IN-2 TFA is a highly tumor-targeted and irreversible PAD4 inhibitor with an IC50 of 1.94 μM. PAD4-IN-2 TFA selectively recognizes sialic acid on tumor surfaces and accumulates in tumor tissues, with distribution in the cytoplasm of tumor cells and nuclei of neutrophils. PAD4-IN-2 TFA inhibits the PAD4-H3cit-NETs (Neutrophil Extracellular Traps) pathway, reduces senescent tumor-associated neutrophils, and promotes M1 macrophage polarization. The compound exhibits potent anti-tumor and anti-metastatic activities and is suitable for breast cancer research .
loading...
    loading...
Cat. No.: HY-139140
CAS No.: 100276-03-7
Target:  

Phosphorylase

Research Areas:  

Metabolic Disease

BAY R3401 is an orally active glycogen phosphorylase inhibitor that can achieve irreversible and non-selective inhibition of hepatic glycogenolysis. BAY R3401 inhibits glycogenolysis in liver cells, with IC50 values of 27.06 and 52.83 μM in HL-7702 and HepG2 cells, respectively. BAY R3401 can be used for the research of type 2 diabetes .
loading...
    loading...
Cat. No.: HY-169688
CAS No.: 1708948-28-0
Target:  

MDM-2/p53 Apoptosis

Research Areas:  

Cancer

NA-17 is a naphthalimide compound with anti-tumor activity and lower toxicity to normal cells like HL-7702 and WI-38. NA-17 exhibits a p53-dependent selective inhibition in various NSCLC cells, inducing the accumulation of active p53 in the mitochondria and nuclei of NSCLC cells. NA-17 can cause cell cycle arrest in the G1 phase, leading to apoptosis and cell death .
loading...
    loading...
Cat. No.: HY-N17767
CAS No.: 1360075-79-1
Leonoside F is a phenylethanoid glycoside compound isolated from the aerial parts of Leonurus japonicus Houtt., which protects liver cells from chemically induced damage. At a concentration of 1×10 -5 M, Leonoside F shows significant hepatoprotective activity against D-galactosamine-induced damage in HL-7702 liver cells, with an inhibition rate of 30.9% .
loading...
    loading...
Cat. No.: HY-172889
CAS No.: 3085191-45-0
Target:  

PI3K HDAC Apoptosis mTOR Akt

Research Areas:  

Cancer

PI3K/HDAC-IN-4 (Compound 31f) is a PI3K/HDAC dual inhibitor (IC50: 0.2μM). PI3K/HDAC-IN-4 shows high selectivity for HDAC1-3 (IC50 values of 75.5 nM, 70.9 nM, and 1.9 nM, respectively). PI3K/HDAC-IN-4 is a potent PIK3 inhibitor with IC50 values of 2.5 nM, 80.5 nM, 10.0 nM, and 57.2 nM for PI3Kα, β, δ, and γ, respectively. PI3K/HDAC-IN-4 significantly induces tumor cell apoptosis by simultaneously inhibiting the PI3K/AKT/mTOR signaling pathway and HDAC1-3. PI3K/HDAC-IN-4 exhibits potent antiproliferative activity in a variety of tumor cell lines (e.g., MV4-11, Jeko-1, HL60, and MCF-7, with IC50 values of 0.2, 0.9, 0.8, and 1.5 μM, respectively). PI3K/HDAC-IN-4 can be used in the study of lymphoma and leukemia .
loading...
    loading...
Cat. No.: HY-183545
CAS No.: 3121405-85-1
sEH-IN-24 is an orally active soluble epoxide hydrolase (sEH) inhibitor with an IC50 of 1.9 nM. sEH-IN-24 inhibits the pro-inflammatory cytokines TNF-α and IL-6. sEH-IN-24 exhibits anti-inflammatory effects and exerts analgesic activity in vivo. sEH-IN-24 prevents pancreatic edema, inflammation and parenchymal atrophy. sEH-IN-24 can be used for the research of acute pancreatitis .
loading...
    loading...